Using Promogran®/Promogran Prisma® on wounds with elevated protease activity: case studies

25 February 2013

This document contains a series of case reports describing the use of PROMOGRAN® and PROMOGRAN PRISMA® (Systagenix) on patients with non-healing chronic wounds with elevated protease activity (EPA), assessed using a WOUNDCHEK™ Protease Status (Systagenix) test. All patients were treated for a minimum of four weeks and the decision to continue with PROMOGRAN®/PROMOGRAN PRISMA® was based on continual assessment. A formal assessment was performed weekly, although patients were instructed to carry out dressing changes more regularly in accordance with product labelling.

Supported by KCI – An Acelity Company

http://www.woundsinternational.com/case-studies/view/using-promogranpromogran-prisma-on-wounds-with-elevated-protease-activity-case-studies

Free for all healthcare professionals

Sign up to the Wounds Group journals





By clicking ‘Subscribe’, you are agreeing that the Wounds Group are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our privacy policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.

I am not a healthcare professional.